

Resubmission

Frovatriptan (Migard[®])

(No. 49/03)

A. Menarini UK

Summary of Recommendation

9 February, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a resubmission.

Frovatriptan (Migard[®]) is accepted for use within NHS Scotland for treatment of the headache phase of migraine attacks with or without aura.

It is the seventh 5HT₁ agonist to be marketed in the UK for this indication. It is less effective at rapidly relieving migraine when compared with the most commonly prescribed drug in this class, but has a similar duration of effect. It is also less expensive than other 5-HT₁ agonists.

Professor David H Lawson
Chairman